H. Gehringer et al., Sequence analysis of the HIV-1 protease coding region of 18 HIV-1-infectedpatients prior to HAART and possible implications on HAART, J CLIN VIRO, 17(2), 2000, pp. 137-141
Background: The majority of HIV-infected patients are treated with highly a
ctive antiretroviral therapy (HAART) consisting of a combination of inhibit
ors of the protease (PIs) and the reverse transcriptase (RTIs). Analysis of
mutations within these enzymes which are associated with development of re
sistance to the applied inhibitors is of major clinical importance. In part
icular, pre-existing mutations in previously untreated individuals may adve
rsely influence the efficacy of HAART. Objectives: The sequences of the pro
tease coding regions of 18 HIV-1-infected patients were analysed prior to H
AART. Study design: DNA was extracted from whole blood samples of HIV-1-inf
ected treatment-naive patients. The protease coding region was amplified by
nested PCR and sequenced directly. The resulting amino acid substitutions
were analysed for known mutations associated with known resistance to PIs,
Results: In all 18 analysed individuals we found 1-10 amino acid substituti
ons per patient in their HIV-1 protease coding region. These mutations occu
rred altogether at 27 positions of the 99 amino acids of the protease codin
g region. Seven of these mutated positions are associated with described re
sistance to PIs. Altogether, 15 of the 18 patients (83%) carried at least o
ne such resistance-conferring: alteration in their protease coding region.
All patients are currently followed up during their present therapy to dete
ct possible resistance formation to the applied PIs. Conclusions: A large v
ariety of pre-existing mutations associated with resistance to PIs was obse
rved prior to their treatment. As none of the patients ever received HAART
before and infection with resistant viral strains is very unlikely, these a
mino acid substitutions evidently reflect natural polymorphism of the HIV-1
protease coding region. (C) 2000 Elsevier Science B.V. All rights reserved
.